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Abstract. The personal health implications behind rare diseases are seldom con-
sidered in widespread medical care. The low incidence rate and complex treatment 
process makes rare disease research an underrated field in the life sciences. How-
ever, it is in these particular conditions that the strongest relations between geno-
types and phenotypes are identified. The rare disease patient manager, detailed in 
this manuscript, presents an innovative perspective for a patient-centric portal in-
tegrating genetic and medical data. With this strategy, patient’s digital records are 
transparently integrated and connected to wet-lab genetics research in a seamless 
working environment. The resulting knowledge base offers multiple data views, 
geared towards medical staff, with patient treatment and monitoring data; genetics 
researchers, through a custom locus-specific database; and patients, who for once 
play an active role in their treatment and rare diseases research. 
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1   Introduction 
Biomedical research states that a rare disease is a particular condition affecting at 
most 1 in 2000 patients. The European Organization for Rare Diseases 
(EURORDIS) estimates that there are approximately 6000 to 8000 rare diseases, 
affecting about 6% to 8% of the population. Within these, about 80% are caused 
by genetic disorders. Due to the reduced incidence of each individual disease, it is 
difficult for patients to find support, both at clinical and psychological level [1]. 
The existence of a small number of patients for each rare disease also delays the 
creation of adequate research studies as it is difficult to identify and coordinate a 
correct cohort [2,3]. Despite the low statistic impact regarding these diseases, the 
combined amount of patients suffering from one of these rare diseases is consider-
ably high. 
The Portuguese National Programme for Rare Disorders, approved in 2008, 
strives towards a concerted system for rare disease tracking and patient monitor-
ing. This endeavor relies heavily on a platform designed to gather information 
from the different stakeholders involved in rare disease patient care, ranging from 
diagnostic labs to health providers up to policy-makers. The set of requirements 
behind such a large-scale project touches miscellaneous research areas. The com-
bination of heterogeneous data from medical reports with patient records and ge-
netic datasets triggers problems in the areas of privacy and security, service com-
position and data integration.  
The solution we envisage relies on edge-of-breed software engineering strate-
gies to provide a seamless working environment for everyone involved in rare dis-
ease research. The platform, a rare disease patient manager, collects and connects 
data for patients during their entire stay in the system. This widespread infor-
mation collection, including medical reports with the initial diagnosis, patient ge-
netic test results or the patient treatment program, is fused into a single knowledge 
base. From there, distinct data views are provided to distinct user roles, each ac-
cessing its own private and independent web information system. 
This Portuguese case study revolves around the creation of reference centres. 
These are more than a single physical institution, enabling the cooperation and 
networking amongst several public entities in the Portuguese health system and 
detaining a wealth of data on patients diagnosed with known rare diseases. This 
organizational structure, involving efforts from multidisciplinary teams, permits 
the best procedures to be available, simplifying processes and minimizing the re-
sources needed. With the innovative rare disease patient manager proposed in this 
manuscript, the reference centres will be endowed with the required set of soft-
ware tools to study the underlying rare disease causes and adverse effects and, 
above all, vastly improve patient care. 
2   Overview 
The importance of a patient’s genetic records in diagnosis and resolution of rare 
diseases has taken medicine to a level where wet-lab research is crucial to unravel 
disease causes and consequences. Hence, databases emerging with information 
about human genome, such as the HGMD (Human Gene Mutation Database) [4] 
or the 1000 Genomes Project [5] retain growing relevance. It is important to col-
lect their public data in novel biomedical software, enabling its usage on the daily 
medical workflow. Despite this growing, the absence of public medical reports, 
specially regarding rare disease patients, indicates the vulnerability of these pa-
tient groups [6].  
Personalized medicine requires the combination of data from both these fields 
along with individual patient information. Data from sequence mutations, genes 
and drug interactions – the genotype – must be combined with data from electron-
ic health records (EHR), DICOM imaging and disease-specific patient data – the 
phenotype. Henceforth, the patient-centric rare disease patient manager offers a 
unique holistic view promoting the collaboration of multiple entities towards the 
study of rare diseases and assessment of patients’ evolution – Fig. 1. 
The de facto standard in rare disease software is Orphanet [7], a web platform 
directed to the general public, health professionals and patients, to inform about 
orphan drugs and rare diseases. It also displays information on specialized consul-
tations, diagnostics, research projects, clinical trials and support groups. Disease-
card [8] is another portal aggregating information regarding rare diseases and 
pointing to key elements for both the education and the biomedical research field. 
Along with these applications, we must take in account EHRs, gathered from 
miscellaneous health information systems, containing clinically relevant patient 
information. Only by mining these reports and collecting them for future analysis 
we will be able to provide the adequate knowledge set for clinicians involved in 
the reference center.  
Locus-specific databases (LSDB) are gene-centric applications, focused on 
providing variant-related features, such as store and search, to gene curators. They 
are usually used by a group of researchers in collaboration, with expertise in a par-
ticular gene or genotype, and provide a valuable tool for analysis of gene expres-
sion and phenotype, both in normal conditions and disease [9].  
Concomitant with the systematic, widespread collection of patient data, LSDBs 
EHR
Drug
Protein
Variation
DICOM
 
 
 
 
Genetics and "omics" data
Med
Bio
Medical data
Rare Disease Patient Manager
 
 
 
Gene
Patients
Fig.  1. The rare disease patient manager seamlessly integrates a collection of patient-centric data, 
combining the quadrants of genetics and “omics” information with miscellaneous medical data in 
a centralized knowledge base. 
ultimate goal is a contribution to the global effort of the Human Variome Project 
(HVP), which aims to collect, curate and distribute all human genetic variation af-
fecting health [10-12]. 
The goal behind the creation of reference centres is to connect individuals from 
disparate research areas and specialized in a particular rare disease. Hence, a ref-
erence centre is composed of multidisciplinary teams with access to resources for 
the diagnosis, treatment and medical monitoring of patients.  
When a patient, whose clinical conditions signal the presence of a known rare 
disease, arrives for medical screening, he is directed to the reference centre, initi-
ating his presence in the rare disease patient manager. Initial contact with the cli-
nicians permits the analysis of symptoms and the evaluation of future treatment 
scenarios. Along with the clinical analysis, patients are sent for genetic testing 
labs, where their genetic sequence will be sampled and explored, searching for 
well-known mutation and other biomarkers. The treatment of rare diseases at this 
level requires a deep collaboration between clinicians and genetics researchers.  
3   Information Workflow 
The rare disease patient manager provides a unified set of tools ranging from the 
integration of patient genetic and clinical data to the various independent data ac-
cess views – Fig. 2.  
Rare disease information in the patient manager knowledge base is built from 
OMIM, Online Mendelian Inheritance in Man [13], and HGNC, HUGO Gene 
Nomenclature Committee [14]. To cope with the increasing data in this field, new 
tools have emerged, namely MUTbase [15], Universal Mutation Database (UMD) 
[16] and Leiden Open-source Variation Database (LOVD) [17]. LOVD innovates 
with the “LSDB-in-a-box” approach: it is offered as a downloadable software 
package containing the full set of tools required for the deployment of a local lo-
cus-specific database. Using LOVD within the rare disease patient manager ena-
bles the quick arrangement of an in-house LSDB, allowing the registration of ge-
netic mutations, linking them to patients in the rare disease patient manager. The 
resulting knowledge network, with direct connections from mutations to patients 
up to diseases represents a true complete view over a rare disease influence area. 
When dealing with rare disease patients, the anonymity and privacy of data are 
regarded as imperative. To cope with the caveat of aggregating all data in a single 
knowledge base, the patient manager provides distinct “data views” over acquired 
information. 
Each view is assigned to a distinct user-role, and enables/disables access to cer-
tain features or data-types. For example, with this approach, reference centre co-
ordinators are differentiated from diagnostic lab technicians: the former are able to 
manage patient monitoring forms whereas the latter can only access the system’s 
LSDB. 
Furthermore, by placing the patient as the central element of this system, he is 
given the power to explore and control his data. Given the personal nature of col-
lected data, patients have the option of not sharing their data to statistical analysis 
or, going the opposite way, and liberate their personal records to whomever they 
want within the reference centre team. Moreover, with the foreseen advances in 
personal electronic health records, patients will be able to get their data out of the 
system and share it with family, physicians or other information systems. 
4 Architecture 
The rare disease patient manager acts as a centralized, patient-centric, information 
portal. To reduce data distribution and increase the overall coherency, the system 
is deployed as a portal of websites. Leveraging on modern web information tech-
nologies, each reference centre is able to launch any number of rare disease-
oriented websites, each with its own customized rare disease patient management 
infrastructure. Despite being a part of the same physical architecture, each rare 
disease patient manager application is virtually independent and unaware of its 
sibling systems.  
In parallel with the main rare disease patient manager system there is a LOVD 
server. This server enables the creation of new customized locus-specific data-
bases that can be used independently. Hence, genetic lab teams within the refer-
ence centre can use their own LSDBs without interfering with the overall rare dis-
ease patient manager architecture. 
Privacy and security are major requirements inherent to the rare disease patient 
manager model. Consequently, distinct types of users are given distinct roles. Role 
assignment is a responsibility of the reference centre coordinator. This role-based 
strategy allows for a transparent data access division: users assigned with a given 
role can only access features and data that are available to that role. 
To complement the LSDB independent usage with the rare disease patient 
manager, the transition between systems needs to be transparent. For this matter, 
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Fig.  2. Data aggregated in the rare disease patient manager is provided to various stakeholders, 
each assigned a distinct role and with its respective data views.  
an innovative data sharing strategy enables cross authentication between the rare 
disease patient manager and the independent LOVD instances. 
5   Discussion 
The rare disease patient manager, overviewed in Fig. 3, provides a solid break-
through in the seamless integration of genetic, medical and patient data. The pa-
tient registry, centralizing medical and genetic data in a single system, delivers a 
fresh and unique perspective to various types of researchers involved in the study 
of rare diseases. This provides comprehensive analysis and medical monitoring of 
patients from the moment they are registered in the system.  
In addition to the aforementioned personalized genetic testing datasets, disease-
specific templates can be created to monitor a broad number of items. This permits 
the creation of custom forms at each rare disease patient manager, enabling both 
the tracking of individual rare disease markers, e.g. neuromuscular disorder level, 
or general phenotypic traits, e.g. blood type or pressure.  Each tracking form con-
tains the title, a short description and a set of fields. The fields can be of different 
types, mimicking the final user interaction: text, true/false, number, multiple se-
lectable options or enumerations. With these fields, the system aims to respond to 
the overall needs of form personalization.  
The innovative integration of gene-centric LSDBs with patient provides a 
tighter connection between a patient’s genetic profile and his medical condition. 
With this, information collected in medical studies is complemented with genetic 
Fig.  3. Rare disease patient manager prototype interface highlighting the patient browser, on 
top, and the independent LOVD application, at the bottom. 
analysis carried out by wet-lab experts. As a result, this distinctive combination of 
data and custom disease tracking supports the creation of modern standardized ra-
re disease monitoring procedures, aiding in the achievement of a more accurate 
diagnosis and of an improved patient care.  
One obvious advantage of this system is its web connectivity, which enables 
the different participants to submit and update the clinical and mutational infor-
mation in a central database using secure protocols. Simultaneously this infor-
mation can be accessed and retrieved in real-time by its registered and authorized 
users. The general purpose solutions currently available are usually focused on in-
tra-institutional use and do not incorporate such features. In addition, due to the 
diseases’ specificities, the system design/architecture should be as flexible as pos-
sible. This platform is actually a “core-system” where the different reference cen-
ters can customize the structure according to their specific needs and workflow. 
Finally, it should be taken into account that genetic information management 
modules are not usually included in general laboratory or patient management sys-
tems. The mutational data integrated in this centralized platform can also be easily 
transferred to an international LSDB or central database. 
6   Conclusions 
Rare diseases are seldom qualified as mainstream life sciences research. Their 
specific features require novel research strategies involving the cooperation of re-
searchers from the clinical, genetics and pharmaceutical domain. Despite success-
ful advances on the last two decades, adequate information structure to support 
these multidisciplinary teams is severely absent. Information from diseases, symp-
toms, diagnostics, drugs and underlying genetic impact is missing or poorly avail-
able. The rare disease patient manager platform described in this manuscript aims 
to overcome these difficulties. This fusion of data from disparate research fields is 
of paramount importance to physicians, genetics researchers and, consequently, 
indispensable to patient care. 
For clinicians, this system represents a breakthrough in rare disease patient data 
management. Clinicians can now track and manage patient data, treatments, diag-
nostics, procedures and genetic profiles in an integrated fashion. As for gene cura-
tors and wet-lab researchers, the system enables the usage of locus-specific data-
bases in an independent yet complementary way, thus enriching patient’s medical 
profiles. At last, for patients, being actively included in their disease-monitoring 
workflow, in the research for better treatments and with total control over personal 
data, represents a new standard in personalized medicine. 
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